127 related articles for article (PubMed ID: 19381446)
1. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas.
Silvani A; Gaviani P; Fiumani A; Scaioli V; Lamperti E; Eoli M; Botturi A; Salmaggi A
J Neurooncol; 2009 Oct; 95(1):61-64. PubMed ID: 19381446
[TBL] [Abstract][Full Text] [Related]
2. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
Stupp R; Tosoni A; Bromberg JEC; Hau P; Campone M; Gijtenbeek J; Frenay M; Breimer L; Wiesinger H; Allgeier A; van den Bent MJ; Bogdahn U; van der Graaf W; Yun HJ; Gorlia T; Lacombe D; Brandes AA
Ann Oncol; 2011 Sep; 22(9):2144-2149. PubMed ID: 21321091
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases.
Freedman RA; Bullitt E; Sun L; Gelman R; Harris G; Ligibel JA; Krop IE; Partridge AH; Eisenberg E; Winer EP; Lin NU
Clin Breast Cancer; 2011 Dec; 11(6):376-83. PubMed ID: 21697017
[TBL] [Abstract][Full Text] [Related]
4. Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.
Morrow PK; Divers S; Provencher L; Luoh SW; Petrella TM; Giurescu M; Schmelter T; Wang Y; Hortobagyi GN; Vahdat LT
Breast Cancer Res Treat; 2010 Oct; 123(3):837-42. PubMed ID: 20697802
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors.
Schmid P; Kiewe P; Possinger K; Korfel A; Lindemann S; Giurescu M; Reif S; Wiesinger H; Thiel E; Kühnhardt D
Ann Oncol; 2010 Mar; 21(3):633-639. PubMed ID: 19880436
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Chan DT; Poon WS; Chan YL; Ng HK
Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021
[TBL] [Abstract][Full Text] [Related]
7. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
Hoffmann J; Fichtner I; Lemm M; Lienau P; Hess-Stumpp H; Rotgeri A; Hofmann B; Klar U
Neuro Oncol; 2009 Apr; 11(2):158-66. PubMed ID: 18780814
[TBL] [Abstract][Full Text] [Related]
8. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KA; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
Neuro Oncol; 2010 Jan; 12(1):95-103. PubMed ID: 20150372
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.
Rustin G; Reed N; Jayson GC; Ledermann JA; Adams M; Perren T; Poole C; Lind M; Persic M; Essapen S; Gore M; Calvert H; Stredder C; Wagner A; Giurescu M; Kaye S
Ann Oncol; 2011 Nov; 22(11):2411-2416. PubMed ID: 21372124
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A
J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
14. Sagopilone, a microtubule stabilizer for the potential treatment of cancer.
Galmarini CM
Curr Opin Investig Drugs; 2009 Dec; 10(12):1359-71. PubMed ID: 19943207
[TBL] [Abstract][Full Text] [Related]
15. Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial.
Arnold D; Voigt W; Kiewe P; Behrmann C; Lindemann S; Reif S; Wiesinger H; Giurescu M; Thiel E; Schmoll HJ
Br J Cancer; 2009 Oct; 101(8):1241-7. PubMed ID: 19773753
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
Peereboom DM; Supko JG; Carson KA; Batchelor T; Phuphanich S; Lesser G; Mikkelsen T; Fisher J; Desideri S; He X; Grossman SA;
J Neurooncol; 2010 Nov; 100(2):261-8. PubMed ID: 20449631
[TBL] [Abstract][Full Text] [Related]
17. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Yang SH; Kim MK; Lee TK; Lee KS; Jeun SS; Park CK; Kang JK; Kim MC; Hong YK
J Korean Med Sci; 2006 Aug; 21(4):739-44. PubMed ID: 16891823
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Wick A; Felsberg J; Steinbach JP; Herrlinger U; Platten M; Blaschke B; Meyermann R; Reifenberger G; Weller M; Wick W
J Clin Oncol; 2007 Aug; 25(22):3357-61. PubMed ID: 17664483
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
